Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter

Trials 26-39 of 39

  • Pembrolizumab and Cryoablation for the Treatment of Patients with Metastatic Urothelial Cancer

    This phase II trial studies the effects of pembrolizumab and cryoablation in treating patients with cancer of the urinary tract (urothelial) that has spread to other parts of the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cryoablation is an intervention which may kill cancer cells using extreme cold. It may help the immune system better recognize the tumor and act against it. Pembrolizumab and cryoablation in combination may work better in treating metastatic urothelial cancer compared to either intervention alone.
    Location: 2 locations

  • A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

    The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy
    Location: 3 locations

  • Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

    A Phase Ib / II, open-label, multicenter, randomized, umbrella study in participants with cisplatin-ineligible MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.
    Location: 3 locations

  • Abexinostat and Pembrolizumab in Treating Patients with MSI-High Locally Advanced or Metastatic Solid Tumors

    This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating patients with microsatellite instability (MSI) solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating patients with solid tumors.
    Location: 2 locations

  • Nivolumab in Treating Patients with Stage II-IV Muscle-Invasive Bladder, Urethra, or Ureter Cancer That Have Undergone Chemoradiotherapy

    This phase II trial studies how well nivolumab works in treating patients with stage II-IV muscle-invasive bladder, urethra, or ureter cancer that have undergone chemoradiotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

    Background: Metastatic urothelial carcinoma is lethal and has no cure. Response rates to current treatments are modest. Researchers want to find new strategies to treat the disease. In this study, they will test a drug called M7824. The drug is a new immunotherapy that blocks the pathways that cancer cells use to stop the immune system from fighting cancer. Objective: To learn if M7824 can help the immune system s ability to fight urothelial cancer. Eligibility: People age 18 and older who have urothelial cancer that has spread to other parts of their body and they have been previously treated with chemotherapy or immunotherapy Design: Participants will be screened with a medical history and physical exam. They will have blood and urine tests. They will have imaging scans. They will have an electrocardiogram to measure heart function. Their ability to perform their normal activities will be evaluated. They may have a tumor biopsy. They will take a pregnancy test if needed. Participants will repeat some of the screening tests during the study. Treatment will be given in a series of 28-day cycles. Participants will get M7824 once every 2 weeks. It is given through an intravenous infusion. For this, a small plastic tube is put into an arm vein. They will get M7824 until their disease gets worse, they have unacceptable side effects, or they decide to stop treatment. Participants will have a follow-up visit 30 days after treatment ends. Then they will be followed every 12 weeks in the clinic or by telephone / email. Follow-up will last indefinitely.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Avelumab in Combination with AXL Inhibitor AVB-S6-500 for the Treatment of Locally Advanced, Unresectable, or Metastatic Urothelial Cancer

    This phase I / II trial studies the side effects and best dose of AVB-S6-500 when given together with avelumab in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. AVB-S6-500 may stop the growth of cancer cells by blocking growth arrest-specific protein 6 (GAS6), a protein for needed for tumor cell growth. Given AVB-S6-500 and avelumab together may work better than giving either one alone in treating patients with urothelial cancer.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

    This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Atezolizumab and PGV001 in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer

    This phase I trial studies the side effects and how well atezolizumab and PGV001 work in treating patients with urothelial cancer that has spread to nearby tissues or lymph nodes (locally advanced) or to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PGV001 is a type of vaccine that is created based on analyzing an individual's tumor tissue. Giving atezolizumab and PGV001 may work better in treating patients with urothelial cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Infigratinib before Surgery for the Treatment of Upper Tract Urothelial Cancer

    This phase Ib trial studies the side effects of infigratinib before surgery in treating patients with upper tract urothelial cancer. Infigratinib may stop the growth of tumor cells by blocking the activities of a gene called FGFR needed for cell growth. Giving infigratinib before surgery may cause the tumor to shrink, which may make the surgical procedure easier and / or reduce the need for more extensive surgery.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed / Refractory Small Cell Lung Cancer

    Background: EP0057 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or "nanoparticle drug conjugate" travels through the blood. Once inside cancer cells, the chemotherapy drug is released from the molecule. Olaparib is a drug that may stop cancer cells from repairing the DNA damage caused by chemotherapy. Researchers want to see how safe it is to give EP0057 and olaparib together and to see how well the combination treats a specific type of lung cancer called small cell lung cancer (SCLC). Objectives: To test the safety and maximum dose of EP0057 and olaparib together. To test how well they treat small cell lung cancer. Eligibility: Adults 18 and older with small cell lung cancer. Design: Participants will be screened with standard cancer care tests. Participants will get the 2 study drugs in 28-day cycles. EP0057 will be given every 2 weeks, through a small plastic tube in an arm vein. Olaparib will be taken by mouth twice a day most days. Participants will keep a pill diary. For Cycle 1, participants will have 3 visits. All other cycles will have 2 visits. At study visits, participants may have: - Blood and hair samples taken - History and Physical exam - Questions about health and side effects - Pregnancy test - Optional tumor biopsy where a piece of tumor is removed by needle after numbing the skin. - CT scan - Injection of EP0057 (twice per cycle) - Olaparib prescription Participants will have a follow-up visit 4 weeks after finish taking the drugs. They will have a physical exam and blood tests. They may have a tumor biopsy. The study team will call the patient every 3 months for follow up after completing the study treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Tesetaxel for Previously Treated Patients With Bladder Cancer

    The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a promising treatment option for some patients. Tesetaxel is an orally administered taxane that is in development as treatment for subjects with advanced cancers. This study is being conducted to determine the efficacy and safety of tesetaxel administered to patients previously treated with chemotherapy for progressive metastatic transitional cell carcinoma of the urothelium.
    Location: See Clinical Trials.gov

  • Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

    This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1 / PD-L1 based regimens
    Location: 2 locations

  • Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer

    This phase III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
    Location: Location information is not yet available.